Targeting growth factor receptors with bispecific molecules

Current Medicinal Chemistry

Volumn 3, Issue 2, 1996, Pages 87-100

  Mokotoff, Michael ^a   Chen, Jian ^b   Zhou, Jie Hua ^b   Ball, Edward D ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 (4 CARBOXYBUTYRAMIDO)CEPHALOSPORIN MUSTARD; BETA LACTAMASE; BOMBESIN DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; DOXYCYCLINE; ENZYME; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IMMUNOTOXIN; INTERLEUKIN 2; INTERMEDIN; MELANOCYTE STIMULATING HORMONE DERIVATIVE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B296; NERVE GROWTH FACTOR; PENTETATE INDIUM IN 111; PENTETREOTIDE; SOMATOSTATIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CANCER; CONJUGATE; DIABETES MELLITUS; DRUG ANALYSIS; DRUG DEVELOPMENT; DRUG TARGETING; DRUG THERAPY; HUMAN; IMMUNOTHERAPY; MELANOMA; RECOMBINANT DNA TECHNOLOGY; REVIEW;

EID: 0029940405     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Aaronson, S.A. Growth factors and cancer. Science, 1991, 254, 1146-1153.
2. Siegfried, J.M. Strategies for identification of peptide growth factors. Pharmac. Ther., 1992, 56, 233-245.
3. Meares, C.F. Introduction to bioconjugate chemistry. In Perspectives in Bioconjugate Chemistry, Claude F. Meares, Ed.; American Chemical Society: Washington, 1993, pp. 1-8.
4. Kohler, G.; Howe, S.C.; Milstein, C. Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines. Eur. J. Immunol., 1976, 6, 292-295.
5. Kohler, G. Derivation and diversification of monoclonal antibodies. Science,1986, 233, 1281-1286.
6. Pastan, I.; Willingham, M.C.; Fitzgerald, D.J.P. Immunotoxins. Cell, 1986, 47, 641-648.
7. Vitetta, E.S.; Fulton, R.J.; May, R.D.; Till, M.; Uhr, J.W. Redesigning nature's poisons to create anti-tumor reagents. Science,1987, 238, 1098-1104.
8. Koppel, G.A. Recent advances with monoclonal antibody drug targeting for the treatment of human cancer. In Perspectives in Bioconjugate Chemistry, Claude F. Meares, Ed.; American Chemical Society: Washington, 1993, pp. 142-152.
9. Fanger, M.W.; Morganelli, P.M.; Guyre, P.M. Bispecific antibodies. Critical Rev. Immunol., 1992, 12, 101-124.
10. Liu, M.A.; Nussbaum, S.R.; Eisen, H.N. Hormone conjugated with antibody to CD3 mediates cytotoxic T cell lysis of human melanoma cells. Science, 1988, 239, 395-398.
11. Carton, P.C.; Jurcic, J.G.; Scott, A.M.; Finn, R.D.; Divgi, C.R.; Graham, M.C.; Jureidini, I.M.; Sgouros, G.; Tyson, D.; Old, L.J.; Larson, S.M.; Scheinberg, D.A. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogentcity. Blood, 1994, 83,1760-1768.
12. Hale, G.; Dyer, M.J.S.; Clark, M.R.; Phillips, J.M.; Marcus, R.; Riechmann, L.; Winter, G.; Waldmann, H. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet, 1988, 2, 1394-1396.
13. Gribben, J.G.; Freedman, A.S.; Neuberg, D.; Roy, D.C.; Blake, K.W.; Woo, S.D., Grossbard, M.L.; Rabinowe, S.N.; Coral, F.; Freeman, G. J.; Ritz, J.; Nadler, L.M. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N. Eng. J. Med., 1991, 325, 1525-1533.
14. Selvaggi, K.J.; Wilson, J.; Mills, L.E.; Cornwell III, G.G.; Hurd, D.; Dodge, W.; Gingrich, R.; Ball, E.D. Improved outcome for high risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody purged bone marrow. Blood, 1994, 83, 1698-1705.
15. Zimmer, A.M.; Spies, S.M.; Waldmann, T.A. Genetically engineered monocolonal antibodies armed with radionuclides. Year in Immunol., 1993, 7, 205-712.
16. New approaches to radiolabeling monoclonal antibodies. Cancer Treat. Res., 1993, 68, 99-109.
17. Pai, L.H.; Pastan, I. Immunotoxin therapy for cancer. J. Am. Med. Assoc., 1993, 269, 78-81.
18. Trail, P.A.; Willner, D.; Lasch, S.J.; Henderson, A.J.; Hofstead, S ; Casazza, A.M.; Firestone, R.A.; Hellström, I.; Hellström, K.E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science, 1993, 261, 212-215.
19. Valone, F.; Kaufmann, P.; Fanger, M.W.; Guyer, P.; Memoli, V.; Lewis, L. Phase Ia/Ib trial of bispecific monoclonal antibody (BsAb) MDX-210 (anti-Her-2/Neu × anti-CD64) for breast or ovarian cancers that over express Her-2/Neu. Proc. Am. Soc. Clin. Oncol., 1994, 13, 298.
20. Silla, L.M.R.; Chen, J.; Zhong, R.K.; Whiteside, T.L.; Ball, E.D. Potentiation of leukemia cell lysis by a bispecific antibody to CD33 and the FcγRIII receptor (CD16) expressed by human natural killer (NK) cells. Br. J. Haematol.,1995, 89, 712-718.
21. Grossbard, M.L.; Press, O.W.; Appelbaum, F.R.; Bernstein, I.D.; Nadler, L.M. Monocolonal antibody-based therapies of leukemia and lymphoma. Blood, 1992, 80, 863-878.
22. Larson, S.M.; Macapinlac, H.A.; Scott, A.M.; Divgi, C.R. Recent achievements in the development of radiolabelled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors. Acta Oncologica, 1993, 32, 709-715.
23. Rosenberg, S.A.; Lotze, M.T.; Muul, L.M.; Chang, A.E.; Avis, F.P.; Leitman, S.; Linehan, W.M.; Robertson, C.N.; Lee, R.E.; Rubin, J.T.; Seipp, C.A.; White, D.E. A progress report on the treatment of 157 patients with advanced cancer using LAK cells and IL-2 or high-dose IL-2 alone. N. Eng. J. Med., 1987, 316, 889-897.
24. Hombach, A.; Jung, W.; Pohl, C.; Renner, C.; Sahin, U.; Schmits, R.; Wolf, J.; Kapp, U.; Diehl, V. A CD16/CD30 bispecific monoclonal antobody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int. J. Cancer, 1993, 55, 830-836.
25. Weiner, L.M.; Holmes, M.; Adams, G.P. A human tumor xenograft model of therapy with a bispecifc monoclonal antibody targeting c-erb-2 and CD16. Cancer Res., 1993, 53, 94-100.
26. 3-bombesin and monoclonal antibody 22 can specifically induce FcγRI (CD64)-dependent monocyte- and neutrophil-mediated lysis of small cell carcinoma of the lung cells. Clin. Cancer Res., 1995, 1, 425-434.
27. Chen, J.; Zhou, J-H.; Mokotoff, M.; Fanger, M.W.; Ball, E.D. Lysis of small cell carcinoma of the lung (SCCL) cells by cytokine-activated monocytes and natural killer cells in the presence of bispecific immunoconjugates containing a gastrin-releasing peptide (GRP) analog or a GRP antagonist. J. Hematotherapy, 1995, 4, 369-376.
28. Chen, J.; Zhou, J-H.; Ball, E.D. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 × 22 (anti-CD33 × anti-CD64). Clin. Cancer Res., 1995, 1, 1319-1325.
29. Chokri, M.; Girard, A.; Borrelly, M.C. Adoptive immunotherapy with bispecific antibodies: targeting through macrophage. Res. Immunol., 1992, 143, 95-99.
30. Fanger, M.W.; Graziano, R.F.; Shen, L.; Guyre, P.M. FcγR cytotoxicity exerted by mononuclear cells. Chem. Immunol., 1989, 47, 214-218.
31. Fanger, M.W.; Morganelli, P.M.; Guyre, P.M. Use of bispecific antibodies in the therapy of tumors. Cancer Treat. Res., 1993, 68, 181-194.
32. Guyre, P.M.; Graziano, R.F.; Vance, B.A.; Morganelli, P.M.; Fanger, M.W. Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function. J. Immunol., 1989, 743, 1650-1655.
33. Co, M.S.; Avdalovic, N.M.; Caron, P.C.; Avdalovic, M.V.; Scheinberg, D.A.; Queen, C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J. Immunol., 1991, 148, 1149-1157.
34. Catane, R.; Longo, D.L. Monoclonal antibodies for cancer therapy, Isr. J. Med Sci., 1988, 24, 471-476.
35. Means, G.E.; Feeney, R.E. Chemical modification of proteins: history and applications. Bioconjugate Chem., 1990, 1, 2-12.
36. Brinkley, M. A brief survey of methods for preparing protein conjugates with dyes, haptens, and cross-linking reagents. Bioconjugate Chem., 1992, 3, 2-13.
37. Pietersz, G.A. The linkage of cytotoxic drugs to monoclonal antibodies for the treatment of cancer. In Perspectives in Bioconjugate Chemistry, Claude F. Meares, Ed.; American Chemical Society: Washington, 1993, pp. 153-159.
38. Senter, P.D.; Wallace, P.M.; Svensson, H.P.; Vrudhula, V.M.; Kerr, D.E., Hellström, I.; Hellström, K.E. Generation of cytotoxic agents by targeted enzymes. Bioconjugate Chem., 1993, 4, 3-9.
39. Senter, P.D.; Saulnier, M.G.; Schreiber, G.J.; Hirschberg, D.L.; Brown, J.P.; Hellström, I.; Hellström, K.E. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. U.S.A., 1988, 85, 4842-4846.
40. Bagshawe, K.D.; Springer, C.J.; Searle, F.; Antoniw, P.; Sharma, S.K.; Melton, R.G.; Sherwood, R.F. A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer, 1988, 58, 700-703.
41. Senter, P.D.; Su, P.C.D.; Katsuragi, T.; Sakai, T.; Cosand, W.L.; Hellström, I.; Hellström, K.E. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconjugate Chem., 1991, 2, 447-451.
42. Bagshawe, K.D. Antibody-directed enzyme prodrug therapy. Clin. Pharmacokinet, 1994, 27, 368-376.
43. Deonarian, M.P.; Epenetos, A.A. Targeting enzymes for cancer therapy: Old enzymes in new roles. Br. J. Cancer, 1994, 70, 786-794.
44. Kerr, D.E.; Schreiber, G.J.; Vrudhula, V.M.; Svensson, H.P.; Hellström, I.; Hellström, K.E.; Senter, P.D. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody β-lactamase conjugates in combination with anticancer prodrugs. Cancer Res., 1995, 55, 3558-3563.
45. Brinkmann, U., Pastan, I. Immunotoxins against cancer. Biochim. Biophys. Acta, 1994, 1198, 27-45.
46. Vallera, D.A. Immunotoxins: will their clinical promise be fulfilled. Blood, 1994, 83, 309-317.
47. Pai, L.H.; Pastan, I. Immunotoxins and recombinant toxins for cancer treatment. Important Adv Oncol., 1994, 3-19.
48. Strand, F.L.; Zuccarelli, L.A.; Williams, K.A.; Lee, S.J.; Lee, T.S.; Antonawich, F.J.; Alves, S.E. Melanotropins as growth factors. In The Melanotropic Peptides, Annals of the New York Academy of Sciences; Hubert Vaudry; Alex N. Eberle, Eds.; The New York Academy of Sciences: New York, 1993; Vol. 680, pp. 29-50.
49. Varga, J.M.; Asato, N.; Lande, S.; Lerner, A.B. Melanotropin-daunomycin conjugate shows receptor-mediated cytotoxicity in cultured murine melanoma cells. Nature, 1977, 267, 56-58.
50. Hadley, M.E. Endocrinology, Prentice-Hall, Inc.:Englewood Cliffs, NJ, 1989, p160.
51. Hruby, V.J.; Wilkes, B.C.; Cody, W.L.; Sawyer, T.K.; Hadley, M.E. Melanotropins: structural, fonformational and biological considerations in the development of superpotent and superprolonged analogs, Pept. Protein Rev., 1984, 3, 1-64.
52. Siegnst, W.; Eberle, A.N. In situ melanin assay for MSH using mouse B16 melanoma cells in culture. Anal. Biochem., 1986, 159, 191-197.
53. Siegrist, W.; Solca, F.; Stutz, S.; Giuffre, L.; Carrel, S.; Girard, J.; Eberle, A.N. Characterization of receptors for α-melanocyte-stimulating hormone on human melanoma cells. Cancer Res., 1989, 49, 6352-6358.
54. Ghanem, G.E.; Comunale, G.; Ubert, A.; Vercammen-Grandjean, A.; LeJeune, F.J. Evidence for alpha-melanocyte-stimulating hormone (α-MSH) receptors on human malignant melanoma cells. Int. J. Cancer, 1988, 41, 248-255.
55. Rainer, A. Preparation of melanocyte stimulating hormone fragments bonded to chelating agents for imaging and therapy of melanomas. Eur. Pat. Appl. EP 498771, 1992.
56. Sawyer, T.K.; Hruby, V.J., Wilkes, B.C.; Draelos, M.T.; Hadley, M.E.; Bergsneider, M. Comparative biological activities of highly potent active site analogues of α-melanotropin. J. Med. Chem., 1982, 25, 1022-1027.
57. Salk, D.; and the multicentre group. Technetium-labeled monoclonal antibodies for imaging metastatic melanoma: results of a multicentre clinical study. Seminars in Oncology, 1988, 15, 608-618.
58. Bard, D.R.; Knight, C.G.; Page-Thomas, D.P. A chelating derivative of α-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma. Br. J. Cancer, 1990, 62, 919-922.
59. Wraight, E.P.; Bard, D.R.; Maughan, T.S.; Knight, C.G.; Page-Thomas, D.P. The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma. Br. J. Radiol., 1992, 65, 112-118.
60. 111In]DTPA-labeled analogues of α-melanocyte-stimulating hormone for melanoma targeting: receptor binding in vitro and in vivo. Int. J. Cancer, 1994, 58,749-755.
61. Tatro, J.B.; Wen, Z.; Entwistle, M.L; Atkins, M.B.; Smith, T.J.; Reichlin, S.; Murphy, J.R. Interaction of an α-melanocyte-stimulating-hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma. Cancer Res., 1992, 52, 2545-2548.
62. Moody, T.W.; Cuttitta, F. Growth factor and peptide receptors in small cell lung cancer. Life Sci., 1993, 52, 1161-1173.
63. Carney, D.N.; Cuttitta, F.; Moody, T.W.; Minna, J.D. Selective Stimulation of Small Cell Lung Cancer Clonal Growth by Bombesin and Gastrin-releasing Peptide. Cancer Res. 1987, 47, 821-825.
64. Mokotoft, M.; Ren, K.; Wong, L.K.; LeFever, A.V.; Lee, P.C. Synthesis and biological evaluation of novel potent antagonists of the bombesin/gastrin releasing peptide receptor. J. Med. Chem., 1992, 35, 4696-4703.
65. 2 and N-terminal aromatic residues. J. Med. Chem., 1994, 37, 439-445.
66. Avis, I.L; Kovacs, T.O.G.; Kasprzyk, P.G.; Treston, A.M.; Bartholomew, R.; Walsh J.H.; Cuttitta, F.; Mulshine, J.L. Preclinical evaluation of an anti-autocrine growth factor monoclonal antibody for treatment of patients with small-cell lung cancer. J. Natl. Cancer Inst, 1991, 83, 1470-1476.
67. Heimbrook, D.C.; Saari, W.S.; Balishin, N.L.; Fisher, T.W.; Friedman, A.; Kiefer, D.M.; Rotberg, N.S.; Wallen, J.W.; Oliff, A. Gastrin releasing peptide antagonists with improved potency and stability. J. Med. Chem. 1991, 34, 2102-2107.
68. 14]Bombesin analogues function as small cell lung cancer bombesin receptor antagonists. Peptides, 1991, 12, 145-149.
69. Radulovic, S.; Cai, R-Z.; Serfozo, P.; Groot, K.; Redding, T.W.; Pinski, J.; Schally, A.V. Biological effects and receptor binding affinities of new pseudopeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi. Int. J. Peptide Protein Res., 1991, 38, 593-600.
70. Gullick, W.J. Prevalence of aberrant expression of the epidermal-growth-factor receptor in human cancers. Brit Med. Bull., 1991. 47, 87-98.
71. Harris, A.L.; Nicholson, S.; Sainsbury, R.; Wright. C.; Farndon, J.R. Epidermal-growth-factor receptor and other oncogenes as prognostic markers. J. Natl. Cancer Inst. Monogr., 1992, 11, 181-187.
72. Dean, C.; Modjtahedi, H.; Eccles, S.; Box, G.; Styles, J. Immunotherapy with antibodies to the EGF receptor. Int. J. Cancer, 1994, Supplement 8, 103-107.
73. Mendelsohn, J. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. J. Natl. Cancer Inst. Monogr., 1992, 13, 125-131.
74. Baselga, J. Mendelsohn, J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res. Treat., 1994, 29, 127-138.
75. + tumor cells by bispecific monoclonal antibodies: requirement of CD3 molecule cross-linking for T-cell activation. Int. J. Cancer, 1993, 55, 931-937.
76. Milstein, C.; Cuello, A.C. Hybrid hybridomas and their use in immunohistochemistry. Nature, 1993, 305, 537-540.
77. Morelli, D.; Sardini, A; Villa, Elena.; Villa, M.L.; Ménard, S.; Colnaghi, M.I. Modulation of drug-induced cytotoxicity by a bispecific monoclonal antibody that recognizes the epidermal growth factor receptor and doxorubicin. Cancer Immunol. Immunother., 1994, 38, 171-177.
78. Braslawsky, G.R.; Kadow, K.; Knipe, J.; McGoff, K.; Edson, M.; Kaneko, T.; Greenfield, R.S. Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity. Cancer Immunol. Immunother., 1991, 33, 367-374.
79. 389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J. Biol. Chem., 1991, 266, 21118-21124.
80. LeMaistre, C.F.; Meneghetti, C.; Howes, L.; Osborne, C.K. Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res. Treat, 1994, 32, 97-103.
81. Goldenberg, A.; Masui, H.; Divgi, C.; Kamrath, H.; Pentlow, K.; Mendelsohn, J. Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. J. Natl. Cancer Inst, 1989, 81, 1616-1625.
82. Krejcarek, G.E.; Tucker, K.L. Covalent attachment of chelating groups to macromolecules. Biochem. Biophys. Res. Commun., 1977, 77, 581-585.
83. HER2 overexpressing tumors. Adv. Exper. Med. Biol., 1994, 353, 83-94.
84. Jardines, L.; Weiss, M.; Fowble, B.; Greene, M. neu(c-erbB-2/HER2) and the epidermal growth factor receptor(EGFR) in breast cancer. Pathobiology, 1993, 61, 268-282.
85. Slamon, D.J.; Godolphin, W.; Jones, L.A.; Holt, J.A.; Wong, S.G.; Keith, D.E.; Levin, W.J.; Stuart, S.G.; Udove, J.; Ullrich, A.; Press, M.F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 1989, 244, 707-712.
86. Berchuck, A.; Rodriquez, G.; Kinney, R.B.; Soper, J.T.; Dodge, R.K.; Clarke-Pearson, D.L.; Bast, R.C. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am. J. Obstet. Gynecol., 1991, 164, 15-21.
87. Yonemura, Y.; Ninomiya, I.; Yamaguchi, A.; Fushida, S.; Kimura, H.; Ohoyama, S.; Miyazaki, I.; Endou, Y.; Tanaka, M.; sasaki, T. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res., 1991, 51, 1034-1038.
88. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res., 1990, 50, 5184-5187.
89. Press, M.F.; Pike, M.C.; Hung, G.; Zhou, J.Y.; Ma, Y.; George, J.; Dietz-Band, J.; James, W.; Slamon, D.J.; Batsakis, J.G.; El-Naggar, A.K. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res., 1994, 54, 5675-5682.
90. Hynes, N.E Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin. Cancer Biol., 1993, 4, 19-26.
91. neu. Methods Enzymol, 1991, 198, 277-290.
92. Tecce, R.; Digiese, G.; Savarese, A.; Trizio, D. Natali, P.G. Characterization of cytotoxic activity of saporin anti-gp185/HER-2 immunotoxins. Int. J. Cancer, 1993, 55, 122-127.
93. Di Lazzaro, C.; Digiesi, G.; Tecce, R.; Lotti, L.V.; Torrisi, M.R.; Natali, P.G. Immunotoxins to the HER-2 oncogene product; functional and ultrastructural analysis of their cytotoxic activity. Cancer Immunol, Immunother., 1994, 39, 318-324.
94. Weiner, L; Holmes, M.; Richeson, A.; Godwin, A.; Adams, G.P.; Hsieh-Ma, S.T.; Ring, D.B.; Alpaugh, R.K. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J. Immunol., 1993, 151, 2877-2886.
95. Ring, D.B.; Clark, R.; Saxena, A. Identity of BCA200 and c-erbB-2 indicated by reactivity of monoclonal antibodies with recombinant c-erbB-2. Mol. Immunol., 1991, 28, 915-917.
96. Valone, F.H.; Kaufman, P.A.; Guyre, P.M.; Lewis, L.D.; Memoli, V.; Deo, Y.; Graziano, R.; Fisher, J.L.; Meyer, L.; Mrozek-Orlowski, M.; Wardell, K.; Guyre, V.; Morley, T.L; Arvizu, C.; Fanger, M.W. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. Clin. Oncol., 1995, 13, 2281-2292.
97. Shalaby, M.R.; Shepard, H.M.; Presta, L.; Rodrigues, M.L.; Beverley, P.C.L.; Feldmann, M.; Carter, P. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J. Exp Med., 1992, 175, 217-225.
98. Shalaby, M.R.; Carter, P.; Maneval, D.; Giltinan, D.; Kotts, C. Bispecific HER2 × CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice. Clin. Immunol. Immunopath., 1995, 74, 185-192.
99. Taniguchi, T.; Minani, Y. The IL-2/IL-2 receptor system: A current overview. Cell, 1993, 73, 5-8.
100. Kreitman, R.J.; FitzGerald, D.; Pastan, I. Targeting growth factor receptors with fusion toxins. Int. J. Immunopharmac., 1992, 14, 465-472.
101. Waldmann, T.A.; Pastan, I.H.; Gansow, O.A.; Junghans, R.P. The multichain interleukin-2 receptor: a target for immunotherapy. Ann. Intern. Med., 1992, 116, 148-160.
102. 486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood, 1992, 79, 2547-2554.
103. 486IL-2 in hematological cancers. Cancer Res., 1993, 53, 3930-3934.
104. Bruns, C.; Stolz, B.; Albert, R.; Marbach, P.; Pless, J. OctreoScan 111 for imaging somatostatin receptor-positive islet cell tumor in rat. Hormone Metab. Res. - Suppl., 1993, 27, 5-11.
105. Tripathy, D.; Benz, C. Growth factors and their receptors. Hemat/Oncol. Clinics North Amer., 1994, 8, 29-50.
106. Reubi, J-C.; Kvols, L.K.; Waser, B.; Nagorney, D.M.; Heitz, P.U.; Carbonequ, J.W.; Reading, C.C.; Moertel, D. Detecetion of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res., 1990, 50, 5959-5977.
107. Edwards, W.B.; Fields, G.G.; Anderson, C.J.; Pajeau, T.S.; Welch, M.J.; Fields, G.B. Generally applicable, convenient solid-phase synthesis and receptor affinities of octreotide analogs. J. Med. Chem., 1994, 37, 3749-3757.
108. 1]-Octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci., 1991, 49, 1583-1591.
109. Friden, P.M.; Walus, L.R.; Watson, P.; Doctrow, S.R.; Kozarich, J.W.; Bäckman, C.; Bergman, H.; Hoffer, B.; Bloom, F.; Granholm, A-C. Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science, 1993, 259, 373-377.
110. Kuus-Reichel, K.; Knott, C.L.; Sam-Fong, P.; Jue, R.A.; Mackensen, D.G.; Corvalan, J.R.F. Production and in vivo characterization of a bifunctional antibody (IVA039.1) with specificity for the mouse interleukin-2 receptor and vinca alkaloids. Hybridoma, 1994, 13, 115-122.